About
Technology
Issues
FAQ
Links
Official Page
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.